IRVINE, Calif., Aug. 22, 2011 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), the global leader in medical aesthetic devices, kicks off the rock of all ages tour with the introduction of The I Wanna Be Sublated, Road to Rejuvenation World Tour – a consumer awareness campaign developed to inspire and revolutionize the landscape of anti-aging with a novel, non-surgical, treatment category in facial rejuvenation - Sublative®. "Sublative rejuvenation is the byproduct of countless product development discussions with the brightest minds in Dermatology and Plastic Surgery," said Louis P. Scafuri, Chief Executive Officer of Syneron. "The driving topic remains centered on what we can do to meet the needs of our customers' patient base and inspire exciting and innovative advancements in our field. Physicians and patients have come to agree that Sublative is the answer to both points."
At first glance the Sublative treatment is already sparking new light for future aesthetic applications as the world's first treatment powered solely by fractionated, bi-polar radio-frequency. "Syneron's expertise as an innovator of radio-frequency technology spans over a decade," said James Bartholomeusz, Global Vice President of Product Development of Syneron. "Our Sublative technology is the latest evolution to captivate the facial rejuvenation world with a novel treatment that transcends through all skin types and age groups. Its versatility amplified with effectiveness positions Sublative as the ideal treatment for the modern-day patient on the go."
Safe and effective for all skin types and age groups, experts will agree that Sublative stands alone in energy-based facial cosmetic applications due to its unique energy delivery model. "To achieve the best possible results when addressing skin imperfections it is essential that the energy reaches below the skin without overheating the top layer of the skin," said Dr. Doris Day, M.D., board-certified Dermatologist at My Clear Skin Day Dermatology and Aesthetics in Manhattan, New York. "Sublative finally provides me with a proven solution to this long-known theory and opens up an option for a much wider patient base in my practice." "For my patients that are looking to rejuvenate their overall complexion without significant downtime, Sublative has been a nice addition to our practice," said Jason Diamond, M.D. board-certified Facial Plastic and Reconstructive Surgeon at The Diamond Face Institute in Beverly Hills, California and featured star on the hit show Dr. 90210.
The coast-to-coast tour is scheduled to reach major cities like Los Angeles and New York in addition to other metropolitan cities such as Phoenix, Denver, Miami, Tampa, San Francisco, San Diego and Chicago. The tour will consist of a variety of different educational events such as open houses, gifting suites and press events. Exclusive Backstage Passes that provide direct access to some of the world-renowned Dermatologists and Plastic Surgeons for a first-hand experience to be Sublated are available for interested media personnel.
For more information about obtaining the Exclusive I Wanna Be Sublated Backstage Pass contact firstname.lastname@example.org or follow our tour updates by liking us on Facebook (Sublative) or following us on Twitter (@sublative). To locate a local treatment provider also visit www.sublativeskin.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. – a company devoted to real technology, real science and real results – is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. The Company's aspiration and commitment to innovation expands Syneron's offering beyond medical devices into the largest in-demand applications in beauty - skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
Additional information can be found at www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
SOURCE Syneron Medical Ltd.